ASH 2014: Malignant clones in response to therapy in JAK2V617F-negative essential thrombocythaemia

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Jean-Jacques Kiladjian (Hôpital Saint-Louis & Université Paris Diderot, Paris, France) discusses using a next-generation sequencing approach to assess the mutational patterns of prognostically-relevant mutations (previously identified in myeloproliferative neoplasms) in calreticulin gene-mutated essential thrombocythaemia (ET) patients during interferon alpha (IFN-α) therapy.

Year of Production:
Running Time:
Color/Sound:

2015
2:24
Color/Sound

Comments are closed.